Bronte Capital increased its Regeneron stake to $146.57m, 12.2% holdings, as earning per share surpassed expectations and institutions' ownership rose to 83.31%.
Bronte Capital Management has increased its stake in Regeneron Pharmaceuticals to $146.57 million, representing 12.2% of its holdings. The company reported earnings of $11.56 per share, surpassing expectations of $8.93. Several institutional investors have adjusted their positions, with Regeneron now 83.31% owned by institutions. Analysts have raised price targets for the stock, with a consensus of $1,109.70, reflecting strong revenue growth and positive market sentiment.
September 10, 2024
14 Articles